A new trading day began on Friday, with Xeris Biopharma Holdings Inc (NASDAQ: XERS) stock price down -5.54% from the previous day of trading, before settling in for the closing price of $3.97. XERS’s price has ranged from $1.69 to $4.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 241.10%. Meanwhile, its annual earnings per share averaged 20.19%. With a float of $137.79 million, this company’s outstanding shares have now reached $149.00 million.
Let’s determine the extent of company efficiency that accounts for 377 employees. In terms of profitability, gross margin is 77.02%, operating margin of -24.11%, and the pretax margin is -35.02%.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xeris Biopharma Holdings Inc is 7.57%, while institutional ownership is 44.80%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 20.19% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Here are Xeris Biopharma Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.17 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Looking closely at Xeris Biopharma Holdings Inc (NASDAQ: XERS), its last 5-days average volume was 2.91 million, which is a jump from its year-to-date volume of 1.69 million. As of the previous 9 days, the stock’s Stochastic %D was 71.90%. Additionally, its Average True Range was 0.18.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 75.18%, which indicates a significant increase from 46.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.11% in the past 14 days, which was higher than the 42.57% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.49, while its 200-day Moving Average is $2.85. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $3.94. Second resistance stands at $4.14. The third major resistance level sits at $4.26. If the price goes on to break the first support level at $3.62, it is likely to go to the next support level at $3.50. Should the price break the second support level, the third support level stands at $3.30.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
With a market capitalization of 559.06 million, the company has a total of 149,081K Shares Outstanding. Currently, annual sales are 163,910 K while annual income is -62,260 K. The company’s previous quarter sales were 54,270 K while its latest quarter income was -15,740 K.
